The short version of GLP-1 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-29 and is reviewed periodically as new material appears.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
== Computer System Validation == This requirement has naturally expanded to encompass computer systems used both in the development and production of, and as a part of pharmaceutical products, medical devices, food, blood establishments, tissue establishments, and clinical trials. In 1983 the FDA published a guide to the inspection of Computerized Systems in Pharmaceutical Processing, also known as the 'bluebook'. Recently both the American FDA and the UK Medicines and Healthcare products Regulatory Agency have added sections to the regulations specifically for the use of computer systems. In the UK, computer validation is covered in Annex 11 of the EU GMP regulations (EMEA 2011). The FDA introduced 21 CFR Part 11 for rules on the use of electronic records, electronic signatures (FDA 1997). The FDA regulation is harmonized with ISO 8402:1994, which treats "verification" and "validation" as separate and distinct terms. On the other hand, many software engineering journal articles and textbooks use the terms "verification" and "validation" interchangeably, or in some cases refer to software "verification, validation, and testing (VV&T)" as if it is a single concept, with no distinction among the three terms.
=== Global expansion === The company elected to expand globally, and acquired other entities. In March 2002, Dr. Reddy's acquired BMS Laboratories, Beverley, and its wholly owned subsidiary Meridian Healthcare, for €14.81 million. These companies deal in oral solids, liquids and packaging, with manufacturing facilities in London and Beverley in the UK. Recently, Dr. Reddy's entered into an R&D and commercialisation agreement with Argenta Discovery Ltd., a private drug development company based in the UK, for the treatment of chronic obstructive pulmonary disease (COPD). Dr. Reddy's entered into a 10-year agreement with Rheoscience A/S of Denmark for the joint development and commercialisation of Balaglitazone (DRF-2593), a molecule for the treatment of type-2 diabetes. Rheoscience holds this product's marketing rights for the European Union and China, while the rights for the US and the rest of the world will be held by Dr. Reddy's. Dr. Reddy's conducted clinical trials of its cardiovascular drug RUS 3108 in Belfast, Northern Ireland, in 2005. The trials were conducted to study the safety and the pharmacokinetic profiles of the drug, which is intended for the treatment of atherosclerosis, a major cause of cardiovascular disorders. Dr. Reddy's entered into a marketing agreement with Eurodrug Laboratories, a pharmaceutical company based in Netherlands, for improving its product portfolio for respiratory diseases. It introduced a second-generation xanthine bronchodilator, doxofylline, which is used for the treatment of asthma and COPD patients.
The West China School/Hospital of Stomatology (Chinese: 四川大学华西口腔医学院 华西口腔医院) is a public tertiary dental school and hospital in Chengdu, Sichuan, China. Owned and operated by the West China Medical Center of Sichuan University, it specializes in dentistry and oral and maxillofacial medicine. The institution traces its origins to the Renji Dental Clinic established in Chengdu in 1907 by Canadian dentist Ashley Woodward Lindsay. The clinic was expanded into a dental hospital in 1912, and in 1917, the dental school of West China Union University was established. Modern histories of dental education identify the West China Union University dental program as the earliest institution of higher dental education in China. The institution is a Grade-III, Class-A specialist hospital and hosts national clinical, research and training programs in oral medicine. In 2020, the National Health Commission entrusted the institution to serve as one of the three National Centers for Stomatology in the country.
Sources: en.wikipedia.org
The list contains recommendations for 523 medications. A separate list for children up to twelve years of age, known as the WHO Model List of Essential Medicines for Children (EMLc), was created in 2007, and is in its 10th edition. It was created to make sure that the needs of children were systematically considered such as availability of proper formulations. Everything in the children's list is also included in the main list. The list and notes are based on the 19th to 24th edition of the main list. Therapeutic alternatives with similar clinical performance are listed for some medicines and they may be considered for national essential medicines lists. The 10th Essential Medicines List for Children was updated in September 2025. Note: An α indicates a medicine is on the complementary list.
=== Autosamplers === Large numbers of samples can be automatically injected onto an HPLC system, by the use of HPLC autosamplers. In addition, HPLC autosamplers have an injection volume and technique which is exactly the same for each injection, consequently they provide a high degree of injection volume precision. It is possible to enable sample stirring within the sampling-chamber, thus promoting homogeneity.
== Mechanism of action == Blasticidin prevents the growth of both eukaryotic and prokaryotic cells. It works by inhibiting termination step of translation and peptide bond formation (to lesser extent) by the ribosome. This means that cells can no longer produce new proteins through translation of mRNA. It is competitive with puromycin suggesting a highly similar binding site.
Ancient seafaring people were aware of the octopus, as evidenced by artworks and designs. It was depicted on coins during the Minoan civilization possibly as early as 1650 BCE and on pottery in Mycenaean Greece around between 1200 and 1100 BCE. A Hawaiian creation myth suggests that the octopus is the lone survivor of a previous age. The legendary sea monster, the kraken is conceived as octopus-like. Similarly, Medusa was compared to an octopus, with her snake-hair resembling the creature's arms. The Akkorokamui is a gigantic octopus-like monster from Ainu folklore, worshipped in Shinto. In the Asuka-era Japanese legend Taishokan, a female diver battles an octopus to recover a stolen jewel, which became the inspiration for woodblock printings. Similarly, in the 1973 novel Gravity's Rainbow an octopus named Grigori attacks a woman on the beach. A battle with an octopus plays a significant role in Victor Hugo's 1866 book Travailleurs de la mer (Toilers of the Sea). The octopus continues to be depicted as antagonistic in films such as Wake of the Red Witch (1948). In political cartoons, octopuses have been used to symbolise empires and large organisations, the arms representing long reach. Octopuses also have an erotic appeal. Japanese erotic art, shunga, includes ukiyo-e woodblock prints such as Katsushika Hokusai's 1814 print Tako to ama (The Dream of the Fisherman's Wife), in which a woman is sexually intertwined with a large and a small octopus. This art style would inspire Pablo Picasso's 1903 drawing An Erotic Drawing: Woman and Octopus.
Sources: en.wikipedia.org
=== Fragment-based === The most common of these uses a group contribution method and is termed cLogP. It has been shown that the log P of a compound can be determined by the sum of its non-overlapping molecular fragments (defined as one or more atoms covalently bound to each other within the molecule). Fragmentary log P values have been determined in a statistical method analogous to the atomic methods (least-squares fitting to a training set). In addition, Hammett-type corrections are included to account of electronic and steric effects. This method in general gives better results than atomic-based methods, but cannot be used to predict partition coefficients for molecules containing unusual functional groups for which the method has not yet been parameterized (most likely because of the lack of experimental data for molecules containing such functional groups).
=== Examples === A RING (Really Interesting New Gene) domain binds the E2 conjugase and might be found to mediate enzymatic activity in the E2-E3 complex An F-box domain (as in the SCF complex) binds the ubiquitinated substrate. (e.g., Cdc 4, which binds the target protein Sic1; Grr1, which binds Cln). A HECT domain, which is involved in the transfer of ubiquitin from the E2 to the substrate.
This ordinary differential equation is what is obtained when the Navier–Stokes equations are written and the flow assumptions applied (additionally, the pressure gradient is solved for). The nonlinear term makes this a very difficult problem to solve analytically (a lengthy implicit solution may be found which involves elliptic integrals and roots of cubic polynomials). Issues with the actual existence of solutions arise for
==== Notes ==== a See Freeze brand § Freeze branding as a painless alternative to mulesing. b See the subsection on human cryobranding in Freeze brand § Usage. c Irwin reports that keeping the iron stationary when branding a dolphin's dorsal fin, rather than rocking it as with livestock, produced a markedly clearer result. d Although adequate marks appeared on the elephant seal's skin at the time of cryobranding none of the marks produced lasted more than 1 year. e Down feathers grew white after cryobranding but did not persist in adult Mallards nor affect the outer contour feathers when they grew in. According to Greenwood, citing Foulks: "melanocytes continually arise from undifferentiated melanoblasts in the dermis during feather growth. Apparently the presence of whitetipped down resulted from the destruction of melanocytes associated with the tip of the developing feather, which were later replaced with active melanocytes before the deposition process terminated. Although birds were treated at ages of 5–10 days, and at various early stages of feather development, no apparent effect on pigmentation of contour feathers occurred." f Herpetologist Charles F. Smith described freeze branding as "[in]effective for bufonids [toads] and other taxa with granular skin surfaces." g All salamanders tested were seriously injured, and some later died. The author does not recommend his method be copied.
The French Laundry event took place on November 6, and between November 5 and December 7 over 442,000 new signatures were submitted and verified; 1,664,010 verified signatures, representing roughly 98% of the final total of 1,719,900, were submitted between November 2020 and March 17, 2021. In response to the criticism, Newsom said in a statement, "While the First Partner and I followed the restaurant's health protocols and took safety precautions, I should have modeled better behavior and not joined the dinner." During the campaign, Newsom compared the recall effort to the attempts to overturn the 2020 United States presidential election. On September 14, 2021, the recall election was held, and only 38% voted to recall Newsom, so he remained in office.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.